Bimatoprost - a review (Q37623833)

21 August 2017

1 reference

title

Bimatoprost - a review (English)

1 reference

21 August 2017

Deepak P Edward

3

0 references

author name string

A Jayaprakash Patil

series ordinal

1

1 reference

21 August 2017

Thasarat S Vajaranant

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

16

1 reference

21 August 2017

page(s)

2759-2768

1 reference

Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Quantitative analysis of conjunctival goblet cells after chronic application of topical drops

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Molecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Update on the mechanism of action of bimatoprost: a review and discussion of new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Bimatoprost, prostamide activity, and conventional drainage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

The pharmacology of bimatoprost (Lumigan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Prostamides (prostaglandin-ethanolamides) and their pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Mechanism of action of bimatoprost (Lumigan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

21 January 2018

The prostaglandin wars

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Flare-up rates with bimatoprost therapy in uveitic glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

A retrospective review of non-responders to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Bimatoprost-induced periocular skin hyperpigmentation: histopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Clinical course of bimatoprost-induced periocular skin changes in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

An update on bimatoprost in glaucoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical beta-blocker monotherapy for the treatment of glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903292649

10.1517/14656560903292649

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference